Skip to main content
Premium Trial:

Request an Annual Quote

Levin Out as CEO of Physiome; Company to Unveil New Business Plan in Two Weeks

NEW YORK, May 22 - Physiome Sciences CEO Jeremy Levin has left the company, which is in the midst of reorganizing itself, GenomeWeb has learned.

 

Levin left approximately one month ago, according to an insider. His name has been removed from the management portion of the company's web site, though he is still listed as a board member.

 

Nicholas Hayes, chief operating officer, has assumed the duties of Levin. Hayes joined Physiome in September 2002. Levin had been president and CEO since 1996.

 

Peter Brooks, vice president of business development and acting vice president for modeling and biological sciences, told GenomeWeb that Physiome will unveil a "new direction" in two weeks.

 

He would not comment when asked to clarify whether the new direction would entail lay offs. It was also unclear what will happen with the company's R&D collaborations, which include deals with 3rd Millennium and IBM.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.